NordicRWE turns Nordic health data into evidence that advances drug development, informs treatment decisions and supports better patient outcomes.
We are a research-driven company based in Nordic countries (including offices in Norway, Sweden and Denmark), combining epidemiology, clinical expertise, advanced analytics and technology development. We work with the Nordic region’s rich health-data infrastructure, including population-based registries, longitudinal cohorts and opportunities for linkage with clinical and molecular information.
Our expertise spans study design, pharmacoepidemiology, treatment pathways, comparative effectiveness and safety, survival analysis, genetic epidemiology and machine learning. We support research from the initial clinical question through analytical planning, execution, interpretation and scientific reporting. Alongside collaborative research with biopharmaceutical companies, we develop methods and solutions for trial emulation, external control arms and drug-signal detection.
For Horizon Europe consortia, we offer a bridge between academic discovery, clinical questions and industry evidence needs. We can contribute rigorous observational study design, longitudinal data analysis, causal inference and the integration of clinical and molecular evidence, with data use governed by the necessary permissions and approvals.
At this brokerage event, we are particularly interested in partnerships in oncology, chronic kidney disease, cardiometabolic health, obesity, predictive biomarkers and personalised medicine.
We welcome discussions with clinical researchers, cohort and trial teams, biomarker laboratories, AI specialists and partners in clinical validation and regulatory translation to build complementary, clinically meaningful European collaborations.